<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21394">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828358</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2016-00973</org_study_id>
    <secondary_id>NCI-2016-00973</secondary_id>
    <secondary_id>AALL15P1</secondary_id>
    <secondary_id>AALL15P1</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <nct_id>NCT02828358</nct_id>
  </id_info>
  <brief_title>Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and MLL Gene Rearrangement</brief_title>
  <official_title>A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and MLL Gene Rearrangement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies the side effects of azacitidine and combination chemotherapy in
      infants with acute lymphoblastic leukemia and myeloid/lymphoid or mixed-lineage leukemia
      (MLL) gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone,
      daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase,
      hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin
      calcium, and thioguanine work in different ways to stop the growth of cancer cells, either
      by killing the cells, by stopping them from dividing, or by stopping them from spreading.
      Giving more than one drug may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the tolerability of azacitidine in addition to Interfant-06 standard
      chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia (ALL) with MLL
      gene rearrangement (MLL-R).

      SECONDARY OBJECTIVES:

      I. To evaluate the biologic activity of azacitidine by pharmacodynamic assessment of global
      deoxyribonucleic acid (DNA) methylation in peripheral blood mononuclear cells (PBMCs) of
      infants treated with azacitidine.

      TERTIARY OBJECTIVES:

      I. To determine the 5 year event-free survival (EFS) of infants with MLL-R treated with
      azacitidine in addition to Interfant-06 standard chemotherapy.

      II. To perform comprehensive genome, exome, methylome, and transcriptome analysis of
      pre-treatment leukemia blasts, remission PMBCs, and refractory or relapsed leukemia blasts
      and to correlate with outcome in the context of the protocol therapy.

      III. To correlate minimal residual disease (MRD) with outcome in the context of the protocol
      therapy.

      IV. To perform pharmacokinetic (PK) testing of azacitidine in infants. V. To test the
      expansion of infant T lymphocytes by stimulation with artificial antigen presenting cells
      identical to those used in chimeric antigen receptor T-cell (CART)-19 production.

      VI. To collect pharmacodynamic (PD) data for asparaginase activity following pegaspargase
      administration in infants.

      OUTLINE:

      INDUCTION CHEMOTHERAPY: Patients receive methotrexate intrathecally (IT) on days 1 and 29,
      prednisolone intravenously (IV) or nasogastrically (NG) three times daily (TID) on days 1-7,
      daunorubicin hydrochloride IV over 1-15 minutes on days 8-9, cytarabine IV over 30 minutes
      on days 8-21 and IT on day 15, dexamethasone orally (PO), NG, or IV TID on days 8-28,
      vincristine sulfate IV over 1 minute on days 8, 15, 22 and 29, pegaspargase IV over 1-2
      hours or intramuscularly (IM) on day 12, and hydrocortisone sodium succinate IT on days 15
      and 29 in the absence of disease progression or unacceptable toxicity. Only patients with
      MLL-R continue to post-induction chemotherapy.

      POST-INDUCTION CHEMOTHERAPY:

      AZACITIDINE BLOCK I: Prior to CONSOLIDATION, patients receive azacitidine IV over 10-40
      minutes daily for 5 days in the absence of disease progression or unacceptable toxicity.

      CONSOLIDATION: Following completion of AZACITIDINE BLOCK I, patients receive
      cyclophosphamide IV over 30-60 minutes on days 1 and 29, mercaptopurine PO or NG daily on
      days 1-28, cytarabine IV or subcutaneously (SC) daily on days 3-6, 10-13, 17-20, and 24-27
      and IT on day 10, methotrexate IT on day 24 , and hydrocortisone sodium succinate IT on days
      10 and 24 in the absence of disease progression or unacceptable toxicity.

      AZACITIDINE BLOCK II: Prior to INTERIM MAINTENANCE, patients receive azacitidine as in
      AZACITIDINE BLOCK I

      INTERIM MAINTENANCE: Following completion of AZACITIDINE BLOCK II, patients receive
      mercaptopurine PO or NG daily on days 1-14, methotrexate IV over 24 hours on days 1 and 8
      and IT on days 2 and 9, hydrocortisone sodium succinate IT on days 2 and 9, leucovorin
      calcium PO or IV on days 2-3 and 9-10, cytarabine IV over 3 hours every 12 hours on days
      15-16 and 22-23 for a total of 8 doses, and pegaspargase IV over 1-2 hours or IM on day 23
      in the absence of disease progression or unacceptable toxicity.

      AZACITIDINE BLOCK III: Prior to DELAYED INTENSIFICATION PART I, patients receive azacitidine
      as in AZACITIDINE BLOCK I.

      DELAYED INTENSIFICATION PART I: Following completion of AZACITIDINE BLOCK III, patients
      receive pegaspargase IV over 1-2 hours or IM on day 1, dexamethasone PO, NG, or IV TID on
      days 1-14 and 15-21 with a taper on days 15-21, thioguanine PO or NG daily on days 1-28,
      vincristine sulfate IV over 1 minute on days 1, 8, 15, and 22, daunorubicin hydrochloride IV
      over 1-15 minutes on days 1, 8, 15, and 22, cytarabine IV or SC on days 2-5, 9-12, 16-19,
      and 23-26 and IT on days 1-15, and hydrocortisone sodium succinate IT on days 1 and 15 in
      the absence of disease progression or unacceptable toxicity.

      AZACITIDINE BLOCK IV: Prior to DELAYED INTENSIFICATION PART II, patients receive azacitidine
      as in AZACITIDINE BLOCK I.

      DELAYED INTENSIFICATION PART II: Following completion of AZACITIDINE BLOCK IV, patients
      receive thioguanine PO or NG daily on days 1-14, cyclophosphamide IV over 15-30 minutes on
      days 1 and 15, cytarabine IV or SC on days 2-5 and 9-12 in the absence of disease
      progression or unacceptable toxicity.

      MAINTENANCE: Following DELAYED INTENSIFICATION PART II, patients receive mercaptopurine PO
      or NG on days 1-168, methotrexate IT on day 1 and 92 and PO once weekly on days 8-91 and
      98-168, hydrocortisone sodium succinate IT on day 1, 57, and 99, and cytarabine IT on day
      57. Starting on day 169, patients receive mercaptopurine PO or NG on days 1-84 and
      methotrexate PO once weekly. Courses repeat every 84 days for 2 years from the start of
      INDUCTION CHEMOTHERAPY in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events of azacitidine and combination chemotherapy, graded according to Common Terminology Criteria for Adverse Events 4.0</measure>
    <time_frame>From the first course of azacitidine administration up to fourth course of azacitidine administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biologic activity, defined as global DNA methylation change in PBMCs</measure>
    <time_frame>Prior to first course of azacitidine up to day 5 of second course of azacitidine</time_frame>
    <description>Will calculate the mean long interspersed nucleotide element-1 (LINE-1) methylation for all patients before and after azacitidine and perform paired t-test analysis to determine if there is significant demethylation in the study population for the tested dose level.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EFS</measure>
    <time_frame>From time of enrollment up to 5 years</time_frame>
    <description>Data from genome, exome, methylome, and transcriptome for pre-treatment leukemia blasts, remission PMBCs, and refractory or relapsed leukemia blasts pre-treatment will be correlated with EFS of patients on protocol therapy. Descriptive analysis will be conducted to correlate MRD with the EFS for the MLL-R patients. PD data for asparaginase activity following pegaspargase administration in infants will be collected and correlated with EFS for the MLL-R patients. Standard errors and confidence intervals for EFS will be calculated using Peto's method.</description>
  </other_outcome>
  <other_outcome>
    <measure>Expansion of infant T lymphocytes by stimulation with artificial antigen presenting cells</measure>
    <time_frame>Up to the end of consolidation therapy, assessed up to 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Genome, exome, methylome, and transcriptome analysis of pre-treatment leukemia blasts, remission PMBCs, and refractory or relapsed leukemia blasts</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Data from genome, exome, methylome, and transcriptome analysis for pre-treatment leukemia blasts, remission PMBCs, and refractory or relapsed leukemia blasts pre-treatment will be correlated with EFS of patients on protocol therapy.</description>
  </other_outcome>
  <other_outcome>
    <measure>Minimal residual disease</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Descriptive analysis will be conducted to correlate MRD with the EFS for the MLL-R patients.</description>
  </other_outcome>
  <other_outcome>
    <measure>PD data for asparaginase activity following pegaspargase administration</measure>
    <time_frame>From 7 days following pegaspargase administration during induction therapy up to 7 days following pegaspargase administration during delayed intensification part 2</time_frame>
    <description>Will be collected and correlated with EFS for the MLL-R patients</description>
  </other_outcome>
  <other_outcome>
    <measure>PK parameters of azacitidine</measure>
    <time_frame>Pre-dose on day 1 and 4, and 5, 30, and 60 minutes, and 4, 6 hours post-dose on day 5 of first course of azacitidine</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Acute Leukemia of Ambiguous Lineage</condition>
  <condition>Childhood B Acute Lymphoblastic Leukemia</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>5 AZC</other_name>
    <other_name>5-AC</other_name>
    <other_name>5-Azacytidine</other_name>
    <other_name>5-AZC</other_name>
    <other_name>Azacytidine</other_name>
    <other_name>Azacytidine, 5-</other_name>
    <other_name>Ladakamycin</other_name>
    <other_name>Mylosar</other_name>
    <other_name>U-18496</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV, SC, IT</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>Cerubidin</other_name>
    <other_name>Cerubidine</other_name>
    <other_name>Cloridrato de Daunorubicina</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>Daunoblastina</other_name>
    <other_name>Daunoblastine</other_name>
    <other_name>Daunomycin Hydrochloride</other_name>
    <other_name>Daunomycin, hydrochloride</other_name>
    <other_name>Daunorubicin.HCl</other_name>
    <other_name>Daunorubicini Hydrochloridum</other_name>
    <other_name>FI-6339</other_name>
    <other_name>Ondena</other_name>
    <other_name>RP-13057</other_name>
    <other_name>Rubidomycin Hydrochloride</other_name>
    <other_name>Rubilem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO, NG, IV</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>Visumetazone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone Sodium Succinate</intervention_name>
    <description>Given IT</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>(11beta)-21-(3-Carboxy-1-oxopropyl)-11,17-dihydroxypregn-4-ene-3,20-dione, Monosodium Salt</other_name>
    <other_name>A-Hydrocort</other_name>
    <other_name>Buccalsone</other_name>
    <other_name>Corlan</other_name>
    <other_name>Cortisol Sodium Succinate</other_name>
    <other_name>Cortop</other_name>
    <other_name>Efcortelan</other_name>
    <other_name>Emergent-EZ</other_name>
    <other_name>Flebocortid</other_name>
    <other_name>Hidroc Clora</other_name>
    <other_name>Hycorace</other_name>
    <other_name>Hydro-Adreson</other_name>
    <other_name>Hydrocort</other_name>
    <other_name>Hydrocortisone 21-Sodium Succinate</other_name>
    <other_name>Hydrocortisone Na Succinate</other_name>
    <other_name>Kinogen</other_name>
    <other_name>Nordicort</other_name>
    <other_name>Nositrol</other_name>
    <other_name>Sinsurrene</other_name>
    <other_name>Sodium hydrocortisone succinate</other_name>
    <other_name>Solu-Cortef</other_name>
    <other_name>Solu-Glyc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <description>Given PO, IV</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>Adinepar</other_name>
    <other_name>Calcifolin</other_name>
    <other_name>Calcium (6S)-Folinate</other_name>
    <other_name>Calcium Folinate</other_name>
    <other_name>Calcium Leucovorin</other_name>
    <other_name>Calfolex</other_name>
    <other_name>Calinat</other_name>
    <other_name>Cehafolin</other_name>
    <other_name>Citofolin</other_name>
    <other_name>Citrec</other_name>
    <other_name>Citrovorum Factor</other_name>
    <other_name>Cromatonbic Folinico</other_name>
    <other_name>Dalisol</other_name>
    <other_name>Disintox</other_name>
    <other_name>Divical</other_name>
    <other_name>Ecofol</other_name>
    <other_name>Emovis</other_name>
    <other_name>Factor, Citrovorum</other_name>
    <other_name>Flynoken A</other_name>
    <other_name>Folaren</other_name>
    <other_name>Folaxin</other_name>
    <other_name>FOLI-cell</other_name>
    <other_name>Foliben</other_name>
    <other_name>Folidan</other_name>
    <other_name>Folidar</other_name>
    <other_name>Folinac</other_name>
    <other_name>Folinate Calcium</other_name>
    <other_name>folinic acid</other_name>
    <other_name>Folinic Acid Calcium Salt Pentahydrate</other_name>
    <other_name>Folinoral</other_name>
    <other_name>Folinvit</other_name>
    <other_name>Foliplus</other_name>
    <other_name>Folix</other_name>
    <other_name>Imo</other_name>
    <other_name>Lederfolat</other_name>
    <other_name>Lederfolin</other_name>
    <other_name>Leucosar</other_name>
    <other_name>leucovorin</other_name>
    <other_name>Rescufolin</other_name>
    <other_name>Rescuvolin</other_name>
    <other_name>Tonofolin</other_name>
    <other_name>Wellcovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO, NG</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>BW 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IT, IV, PO</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>L-Asparaginase with Polyethylene Glycol</other_name>
    <other_name>Oncaspar</other_name>
    <other_name>PEG-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase</other_name>
    <other_name>PEG-L-Asparaginase (Enzon - Kyowa Hakko)</other_name>
    <other_name>PEGLA</other_name>
    <other_name>Polyethylene Glycol L-Asparaginase</other_name>
    <other_name>Polyethylene Glycol-L-Asparaginase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Given PO, NG</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione</other_name>
    <other_name>.delta.1-Hydrocortisone</other_name>
    <other_name>Adnisolone</other_name>
    <other_name>Aprednislon</other_name>
    <other_name>Capsoid</other_name>
    <other_name>Cortalone</other_name>
    <other_name>Cortisolone</other_name>
    <other_name>Dacortin H</other_name>
    <other_name>Decaprednil</other_name>
    <other_name>Decortin H</other_name>
    <other_name>Delta(1)Hydrocortisone</other_name>
    <other_name>Delta- Cortef</other_name>
    <other_name>Delta-Cortef</other_name>
    <other_name>Delta-Diona</other_name>
    <other_name>Delta-F</other_name>
    <other_name>Delta-Phoricol</other_name>
    <other_name>Delta1-dehydro-hydrocortisone</other_name>
    <other_name>Deltacortril</other_name>
    <other_name>Deltahydrocortisone</other_name>
    <other_name>Deltasolone</other_name>
    <other_name>Deltidrosol</other_name>
    <other_name>Dhasolone</other_name>
    <other_name>Di-Adreson-F</other_name>
    <other_name>Dontisolon D</other_name>
    <other_name>Estilsona</other_name>
    <other_name>Fisopred</other_name>
    <other_name>Frisolona</other_name>
    <other_name>Gupisone</other_name>
    <other_name>Hostacortin H</other_name>
    <other_name>Hydeltra</other_name>
    <other_name>Hydeltrasol</other_name>
    <other_name>Klismacort</other_name>
    <other_name>Kuhlprednon</other_name>
    <other_name>Lenisolone</other_name>
    <other_name>Lepi-Cortinolo</other_name>
    <other_name>Linola-H N</other_name>
    <other_name>Linola-H-Fett N</other_name>
    <other_name>Longiprednil</other_name>
    <other_name>Metacortandralone</other_name>
    <other_name>Meti Derm</other_name>
    <other_name>Meticortelone</other_name>
    <other_name>Opredsone</other_name>
    <other_name>Panafcortelone</other_name>
    <other_name>Precortisyl</other_name>
    <other_name>Pred-Clysma</other_name>
    <other_name>Predeltilone</other_name>
    <other_name>Predni-Coelin</other_name>
    <other_name>Predni-Helvacort</other_name>
    <other_name>Prednicortelone</other_name>
    <other_name>Prednisolonum</other_name>
    <other_name>Prelone</other_name>
    <other_name>Prenilone</other_name>
    <other_name>Sterane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>Given PO, NG</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>2-Amino 6MP</other_name>
    <other_name>2-Amino-1,7-dihydro-6H-purine-6-thione</other_name>
    <other_name>2-Amino-6-mercaptopurine</other_name>
    <other_name>2-Amino-6-purinethiol</other_name>
    <other_name>2-Aminopurin-6-thiol</other_name>
    <other_name>2-Aminopurine-6(1H)-thione</other_name>
    <other_name>2-Aminopurine-6-thiol</other_name>
    <other_name>2-Mercapto-6-aminopurine</other_name>
    <other_name>6-Amino-2-mercaptopurine</other_name>
    <other_name>6-Mercapto-2-aminopurine</other_name>
    <other_name>6-Mercaptoguanine</other_name>
    <other_name>6-TG</other_name>
    <other_name>6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)</other_name>
    <other_name>BW 5071</other_name>
    <other_name>Lanvis</other_name>
    <other_name>Tabloid</other_name>
    <other_name>Tioguanin</other_name>
    <other_name>Tioguanine</other_name>
    <other_name>Wellcome U3B</other_name>
    <other_name>WR-1141</other_name>
    <other_name>X 27</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (azacitidine, combination chemotherapy)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have newly diagnosed B lymphoblastic leukemia (2008 World Health
             Organization [WHO] classification) (also termed B-precursor acute lymphoblastic
             leukemia) or acute leukemia of ambiguous lineage; patients with mixed phenotype acute
             leukemia are eligible, provided the morphology and immunophenotype are at least 50% B
             lymphoblastic

          -  Central nervous system (CNS) status must be determined based on a sample obtained
             prior to the administration of any systemic or intrathecal chemotherapy, with the
             exception of steroid pretreatment

        Exclusion Criteria:

          -  Patients with known MLL germline (MLL-G) leukemia prior to enrollment

          -  Patients with Down syndrome

          -  Patients with secondary B acute lymphoblastic leukemia (B-ALL) that developed after
             treatment of a prior malignancy with cytotoxic chemotherapy

          -  With the exception of steroid pretreatment or the administration of intrathecal
             methotrexate per protocol dosing, receipt of any other prior cytotoxic chemotherapy
             for either the current diagnosis of B-ALL or any cancer diagnosed prior to the
             initiation of protocol therapy on AALL15P1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>364 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin Guest</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin M. Guest</last_name>
      <phone>816-234-3265</phone>
    </contact>
    <investigator>
      <last_name>Erin M. Guest</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>January 31, 2017</lastchanged_date>
  <firstreceived_date>July 7, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Cortisone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
